Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure

QJM: An International Journal of Medicine

Volumn 91, Issue 3, 1998, Pages 199-203

  Anker, S D ^a,c   Volterrani, M ^a   Egerer, K R ^b   Felton, C V ^a   Kox, W J ^a   Poole Wilson, P A ^a   Coats, A J S ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HUMBOLDT UNIVERSITY   (Germany)

^c NHLI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARM; ARTICLE; CACHEXIA; CLINICAL ARTICLE; EXERCISE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LEG BLOOD FLOW; MALE; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASODILATATION;

EID: 0031929473     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.3.199     Document Type: Article

References (23)

1. Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation 1984; 69:1079-87.
2. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Circulation 1989; 80:769-81.
3. Volterrani M, Clark AL, Ludman PF, et al. Predictors of exercise capacity in chronic heart failure. Eur Heart J 1994; 15:801-9.
4. Massie B, Conway M, Yonge R, et al. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow. Circulation 1987; 76:1009-19.
5. Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatiguability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 1997; 18:259-69.
6. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-41.
7. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J 1991; 66:356-8.
8. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor α in severe congestive cardiac failure. Br Heart J 1993; 70:141-3.
9. Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantely acute anorexia. J Clin Invest 1990; 86:2014-24.
10. Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Circulation 1994; 90:12-16.
11. Tedgui A, Bernard C. Cytokines and vascular reactivity. Heart Failure 1995; 11:159-65.
12. Anker SD, Ponikowski P, Varney S, Clark AL, Chua TP, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJS. Wasting as independent risk factor of survival in chronic heart failure. Lancet 1997; 349:1050-3.
13. Anker SD, Chua TP, Swan JW, Ponikowski P, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJS. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: The importance for cardiac cachexia. Circulation 1997; 96:526-34.
14. Engelberts I, Stephens S, Francot GJM, Van der Linden CJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338:515-16.
15. Anker SD, Egerer K, Volk H-D, Kox WJ, Poole-Wilson PA, Coats AJS. Elevated soluble CD14 receptors and altert cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-30.
16. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Ann Rev Cell Biol 1994; 10:317-43.
17. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87:3629-32.
18. Yoshizumi M, Perella MA, Burnett JCJ, Lee M-E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 733:205-9.
19. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol 1986; 137:3295-8.
20. Goldhaber JI, Kim KH, Natterson PD, Lawrence T, Yang P, Weiss JN. Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996; 271:H1449-55.
21. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993 Nov; 92(5):2303-12.
22. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 1988; 140:2994-9.
23. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479-86.